São Paulo (site of a large proportion of Leronlimab trials) is among the most vaccinated metropolitan areas in Brazil.
City of São Paulo has vaccinated 96.1% of adult population with first dose
This demonstrates a significant effort by São Paulo city and state to protect its citizens.
However, first dose is only 30.7% effective against Delta.
Significant need remains for effective therapeutics, in Brazil as elsewhere. Opportunity for leronlimab to demonstrate efficacy remains mostly undiminished.